65,437 trials
Fibromyalgia
Primary: Health-related Quality of Life Assessed With the Revised Fibromyalgia Impact Questionnaire — 53.7; 55.5 score on a scale — p=0.740
Healthy Subjects
Primary: Maximum Observed Plasma Concentration (Cmax) of Guaifenesin — 1076.37; 1223.89 ng/ml
Chronic Hepatitis C
Primary: Percentage of Participants Achieving Sustained Virological Response 12 Weeks Post-treatment (SVR12) — 90.7 percentage of participants
Malignant Solid Tumor · Solid Tumor · Metastatic Tumor
Primary: Recommended Dose for Phase 2 Studies — 90 mg every other day for 21 days
Degenerative Changes · Stenosis · Spondylosis
Primary: Number of Posterolateral Gutters That Have Evidence of Arthrodesis (Fusion) at 3, 6, 12, and 24 Months, as Measured by X-rays. — 39; 34; 42; 36 Posterolateral Gutters
Healthy Volunteer
Primary: Number of Participants With Clinically Significant Effects — 0; 0; 7; 4 Participants
Hormone-Resistant Prostate Cancer · Prostate Adenocarcinoma · Recurrent Prostate Carcinoma
Primary: cTTP
HIV Infections
Primary: Time to Detectable Virus in the Remune Plus ALVAC Group and the Placebo Group — 24.5; 13.5 days
Infections, Meningococcal
Primary: Percentage of Participants With rSBA-Antibody Titers Greater Than or Equal to (>=) 1:8 For Each of the 4 Serogroups at 24 Months After Booster Vaccination — 98.4; 23.8…
Hernia, Inguinal
Primary: Inter-rater Agreement, 5-point Scale — 0.57 ICC
Pharmacokinetics Study in de Novo Kidney Transplantation
Primary: ANCOVA Model for Change in Nankivell GFR (mL/Min) at Month 6, Without Replacement of Missing Values (Full Analysis Set) — 47.65; 38.60 mL/min — p=0.0003
Breast Neoplasms
Primary: Percentage of Participants With Objective Response (OR) Assessed by Response Evaluation Criteria in Solid Tumours Version (RECIST) 1.1 — 18; 31 Percentage of participants
Sickle Cell Disease
Primary: Time (Minutes) From Arrival to Center to Time First Dose of Parenteral Pain Medication Administered — 125.3; 61.8 minutes
Neoplasms
Primary: Number of Participants With Adverse Events (AEs) — 6; 3; 3; 11 Participants
Coronary Artery Disease
Primary: The Primary Endpoint is a Composite of Death and Cardiovascular Events (Clinical and Silent MI, Cardiac Failure, Cardiac Arrest, Pulmonary Embolism, and Stroke) Measured…